CaSR activation triggers mandibular overgrowth in fMP patients and mice

Mandibular prognathism (MP) is the most common type of dento-maxillofacial deformity in East Asian populations. Genetic studies have revealed several MP-associated loci, suggesting that MP could be inherited as familial MP (fMP). However, functional verifications and in-depth mechanistic investigations of these loci are limited. For this study, we recruited 5 fMP families with 17 fMP members and 7 normal members. We first compared the clinical features of the 17 fMP members with 31 non-familial MP patients, finding a stronger mandibular overgrowth phenotype in the fMP subjects. Next, we performed whole-exome sequencing (WES) analysis with members of the 5 fMP families and singled out a potential fMP-associated pathogenic variant in the CASR gene—namely, rs117375173—the mutation introduces an amino acid substitution (A601G) in exon 7 and confers gain-of-function in Calcium-Sensing Receptor (CaSR). The rs11735173 variant changes the CaSR protein structure toward a semi-active state, similar to CaSR activated by L-tryptophan (L-Trp). To verify the regulating roles of CASR in mandibular bone growth, we further generated different mouse models with abnormal CaSR function. L-Trp administration effectively activate CaSR/GNAQ expression in vivo and in vitro. The MC3T3-E1 cell line transfected with CaSR with rs117375173 showed increased osteogenic differentiation and collagen synthesis at transcriptional level. Local injection of L-Trp in the mandible of growing mice significantly increased the mandibular length and BMD, due to activated osteogenic activity and suppressed bone resorption. At the same time, loss-of-function of CaSR in osteogenic progenitors caused mandibular growth retardation in Gli1-CreER; Casrfl/fl; tdTomatofl/+ mice. In conclusion, our study reveals that abnormal functioning of CaSR affects mandibular bone development and may contribute to the pathogenesis of fMP, providing a theoretical and experimental basis for the early diagnosis of and therapeutic strategies for fMP in clinical practice. Overall design: The MC3T3-E1 cells were plated at a cell density between 500,000 and 800,000 cells/well in a 6-well plate and cultured with Dulbecco's modified Eagle's medium?+?GlutaMAX (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. After 24?h, the CaSRmut plasmid and CaSRwt plasmid were transfected into the cells with Lipofectamine 3000 (Thermo Fisher Scientific). After 48?h, cells were harvested, and RNA was extracted using TRIzol™ (Thermo Fisher Scientific). RNA integrity was assessed using the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). And then bulk RNA sequencing.